

June 27, 2025

Kissei Pharmaceutical Co., Ltd.

Status of dialogue with shareholders, investors and others (Results for the fiscal year 2024)

● Policy on responding to our shareholders, investors and others

Our company promotes constructive dialogue with shareholders, investors, and others in accordance with the "the Kissei Pharmaceutical Corporate Governance Basic Policy" as follows.

1. Regarding dialogue with shareholders, the Public Relations Department will be responsible and will appropriately respond in cooperation with the President (COO), representative Director, and relevant departments.
2. In the disclosure and explanation of financial statements, the corporate planning department, accounting department, and general affairs department hold regular meetings with the public relations department to exchange opinions based on their respective areas of expertise and support dialogue with shareholders.
3. We conduct activities to deepen the understanding of our management strategy and business environment through shareholder briefings and information disclosure on our company website.
4. In dialogues with shareholders, we have established the "the Kissei Pharmaceutical Information Disclosure Policy" and, in accordance with laws and internal regulations, are mindful to ensure that no disparities arise among shareholders regarding the disclosure of important facts, while also paying close attention to the handling of insider information.

● Financial results briefing (for analysts and institutional investors)

【Event Results (Fiscal 2024)】

| Month | Contents | Our company responders | Participants |
|----------|------------------|--|-----------------------|
| May 2024 | Full Fiscal Year | •COO •Managing director and department manager of Corporate Finance and Management Department (CFO) • Senior corporate officer, Clinical Development Division Director | Total 51 participants |

| | | | |
|---------------|--------------------------|--|-----------------------|
| November 2024 | Second Quarter (Interim) | <ul style="list-style-type: none"> • COO • CFO • Senior corporate officer, Clinical Development Division Director | Total 41 participants |
|---------------|--------------------------|--|-----------------------|

● **R&D Meeting (for analysts and institutional investors)**

【Event Results (Fiscal 2024) 】

| Month | Contents | Our company responders | Participants |
|------------|--|--|-----------------------|
| March 2025 | Current Status of Drug Discovery Research and Development Pipeline | <ul style="list-style-type: none"> • COO • Member of the Board, Research Division Director • Senior corporate officer, Clinical Development Division Director | Total 37 participants |

● **Individual IR Meeting**

【Meeting Results (Fiscal 2024) 】

| Investors, etc. | Number of dialogues | Our company responders |
|--------------------|---------------------|--|
| Sell-side analyst | 19 times | the Chairman (CEO) (1 time), CFO (1 time), Member of the Board, Research Division Director (1 time), IR staff (19 times), etc. |
| Domestic investors | 58 times | COO (5 times), CFO (2 times), IR staff (58 times), etc. |
| Overseas investors | 12 times | COO (1 time), IR staff (12 times), etc. |

● **Major themes and concerns of dialogues**

① Business environment

- Trends in the entire pharmaceutical industry (including the impact of drug price revisions)
- Outlook of the drug price system and its impact on performance (impact of selected treatment system, drug price revision, etc.)

② Operating Results

- Current status of the Pharmaceutical Business and sales trends of key products

- Situation by segment
- Medium to long-term performance outlook (outlook for the next medium-term management plan, disclosure methods, etc.)

③ ESG

- Thoughts and initiatives regarding sustainability
- Human Resource Strategy
- Composition of the Board of Directors

④ Capital Policy

- Efforts towards exceeding P/B ratio over 1.0
- Shareholder Return policy
- Outlook on Cash Allocation

● **Status of feedback to management and the Board of Directors regarding shareholder opinions and concerns identified through dialogue**

- Opinions expressed during discussions with shareholders and investors are shared with the Board of Directors as appropriate and are utilized in reviewing our management strategy. In the fiscal year 2024, we utilized various forms of information disclosure, including the re-identification of materiality, the formulation of the "Annual Report", and the new mid-term management plan "Beyond 80".
- For the new mid-term management plan "Beyond 80," please refer to our website "Mid-Term Management Plan." (<https://www.kissei.co.jp/investor/policy/plan/>)